Part:BBa_K3504010
Multi-epitope TNBC Vaccine regulated by SGP 30
Part Description
A composite of parts (BBa_K3504004,BBa_K3504011,BBa_K3504007,BBa_K3504008) Which form as a whole a multiepitope vaccine accompanied by Gly-Ala repeats and mir-126 binding site by which work in protecting the circuit from immune response attack.
Usage
SG RNA is transcribed from the SG promoter and serves as template for translation of viral structure protein e.g.:capsid,E2 and E1 which gives alpha virus attractive systems for designing self replicating vectors for delivery and expression of heterogeneous genetic information. It’s also used for amplification and replication by the VEEV replication complex SG RNA is transcribed from a promoter located in the alpha virus specific RNA replication intermediate and is not further amplified. SG promoter transcribes RNA encoding proteins of interest and encodes the same (3 CSE ) and poly A tail as the viral genome but contains a different (5 UTR) and lacks the (51-nt CSE). We used it as a control to demonstrates a standard level of RNA synthesis and heterogeneous protein expression. Immune-modulating adjuvants and PADRE (Pan HLA-DR epitopes) sequence were added with epitopes sequence to enhance the immunogenicity. All the epitopes, adjuvants and PADRE sequence were joined by linkers. Heat-shock proteins (hsp) provide a natural link between innate and adaptive immune responses by combining the ideal properties of antigen carriage (chaperoning), targeting and activation of antigen-presenting cells (APC), including dendritic cells (DC). EBNA1 glycine-alanine repeat (GAR) domain when inserted in cis with CTL epitope can inhibit antigen presentation through preventing cytotoxic T-lymphocyte-epitope generation. GAR appears to inhibit the proteosomal degradation of indicator proteins into which the gly-ala repeat is introduced, therefore evades the recognition by CTLs. previous findings show that the Gly-Ala repeat prevents presentation of MHC class I-restricted epitopes through the inhibiting the ubiquitin/proteasome pathway.
Characterization
Improvements
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal XhoI site found at 2300
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 741
Illegal NgoMIV site found at 765
Illegal NgoMIV site found at 963
Illegal NgoMIV site found at 1104
Illegal NgoMIV site found at 1143
Illegal NgoMIV site found at 1206
Illegal NgoMIV site found at 1272 - 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 1634
Illegal BsaI.rc site found at 2120
Illegal SapI.rc site found at 1505
None |